Skip to main content
. Author manuscript; available in PMC: 2020 Jun 29.
Published in final edited form as: J Immunother. 2010 Oct;33(8):828–833. doi: 10.1097/CJI.0b013e3181eec14c

TABLE 2.

Treatment Characteristics: Few Doses Tolerated Before Debilitating Disease Progression

Total Doses No. Patients
1 3
2 8*
3 4
4 (1 course) 7
5
6 2
7 1
8 (2 courses) 2
Grade 3 to 4 Immune-mediated adverse events
 Colitis 1
 Hypophysitis 1
 Encephalitis 1
*

1 stopped for colitis, 1 stopped for encephalitis.

1 stopped for hypophysitis.